'Showed hematologic responses' presentation slideshows

Nilotinib as an alternate medication for Imatinib-Resistant CML

Chronic Myeloid Leukemia or CML forms from the clonal expansion of stem cells (pluripotent hematopoietic) that contains an active fusion gene/protein known as BCR/ABL. This protein shows organized tyrosine activity and enables the leukemic cells to grow and also provide resistance to apoptosis. However, a small percentage of CML patient have shown resistance to the Imatinib medication and as a result, taking Imatinib may result in increased toxicity for them. To counter the Imatinib-Resistant CML, several medications (which were used as tyrosine kinase inhibitor or TKI) were tested. Source: https://www.cancercurepharmacy.com/BlogDetails.aspx?Title=Nilotinib-as-an-alternate-medication-for-Imatinib-Resistant-CML

44 views • 3 slides